연구동향 분석

Chemoinformatics-Based Drug Design for Non-Covalent Inhibitors of Keap1-Nrf2 Protein-Protein Interaction

ASHWINI MACHHINDRA LONDHE 2020년

논문상세정보
인용/피인용
' Chemoinformatics-Based Drug Design for Non-Covalent Inhibitors of Keap1-Nrf2 Protein-Protein Interaction' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Keap1-Nrf2
  • computer based drug design
  • docking
  • molecularmodeling
  • pharmacophore
  • umbrella sampling
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
26 0

0.0%

' Chemoinformatics-Based Drug Design for Non-Covalent Inhibitors of Keap1-Nrf2 Protein-Protein Interaction' 의 참고문헌

  • Role of ROS and RNS sources in physiological and pathologicalConditions
    [2016]
  • Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway byChemopreventive agents
    [2010]
  • Replacement of a naphthalene scaffold in Kelch-like ECH-sssociated protein 1 ( KEAP1 ) /Nuclear factor ( erythroid-derived 2 ) like 2 ( NRF2 ) inhibitors
    61 ( 17 ) , 8029-8047 . [2018]
  • Regulation of the Nrf2–Keap1 antioxidant response by the ubiquitin proteasome system : an insight intoCullin-ring ubiquitin ligases
    13 ( 11 ) , 1699-1712 . [2010]
  • Recent advances in ligandbased drug design : relevance and utility of theConformationally sampled pharmacophore approach
    7 ( 1 ) , 10-22 . [2011]
  • Potential mean force from umbrella sampling simulations : whatCan we learn and what is missed ?
    15 ( 4 ) , 2433-2443 [2019]
  • Discovery Studio Modeling Environment , Release 20182020 , R. Dassault Systèmes
  • Computer-aided drug discovery and development ( CADDD ) : in siliCochemiCobiological approach
    171 ( 2 ) , 165- 176 . [2008]
  • Activators and inhibitors of NRF2 : a review of their potential for clinical development
    [2019]
  • A database for the predicted pharmacophoric features of medicinal compounds
    6 ( 4 ) , 167 . [2011]
  • 'p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming '
    7 ( 1 ) , 1-16 . [2016]
  • 'Updated research and applications of small molecule inhibitors of Keap1-Nrf2 protein-protein interaction : a review
    21 ( 16 ) , 1861-1870 . [2014]
  • 'The transcription factor Nrf2 as a new therapeutic target in Parkinson 's disease
    13 ( 3 ) , 319-329 [2009]
  • 'The role of antioxidants and antioxidant-related enzymes in protective responses to environmentally induced oxidative stress
    674 ( 1-2 ) , 137-147 . [2009]
  • 'The role of Nrf2 signaling in counteracting neurodegenerative diseases
    285 ( 19 ) , 3576-3590 . [2018]
  • 'The role of Nrf2 in liver disease : Novel molecular mechanisms and therapeutic approaches
    9 , 1428 [2019]
  • 'The protective role of antioxidants in the defence against ROS/RNS-mediated environmental pollution
    [2014]
  • 'The process of structure-based drug design
    10 ( 9 ) , 787-797 . [2003]
  • 'The kelch repeat superfamily of proteins : propellers of cell function
    10 ( 1 ) , 17-24 . [2000]
  • 'The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment
    2 ( 5 ) , a006148 [2012]
  • 'The anti-inflammatory and anti-oxidant mechanisms of the Keap1/Nrf2/ARE signaling pathway in chronic diseases
    10 ( 3 ) , 637 [2019]
  • 'The Nrf2 cell defence pathway : Keap1-dependent and-independent mechanisms of regulation
    85 ( 6 ) , 705-717 . [2013]
  • 'Structure of the Keap1 : Nrf2 interface provides mechanistic insight into Nrf2 signaling
    25 ( 15 ) , 3605-3617 . [2006]
  • 'Structural basis of Keap1 interactions with Nrf2 '
    88 , 101-107 [2015]
  • 'Software for molecular docking : a review
    9 ( 2 ) , 91-102 . [2017]
  • 'Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism
    21 ( 14 ) , 4011-4019 [2013]
  • 'Shaping the Nrf2-ARE-related pathways in Alzheimer ’ s and Parkinson ’ s diseases
    [2019]
  • 'Role of nrf2 in oxidative stress and toxicity
    53 , 401-426 [2013]
  • 'Resveratrol Attenuates Intermittent Hypoxia-Induced Lung Injury by Activating the Nrf2/ARE Pathway
    198 , 323-331 [2020]
  • 'Reactive oxygen species and antioxidant defense in human gastrointestinal diseases
    5 ( 4 ) , 250-258 [2016]
  • 'Prospective type 1 and type 2 disulfides of Keap1 protein
    21 ( 10 ) , 2051-2060 . [2008]
  • 'Probing the structural requirements of nonelectrophilic naphthalene-based Nrf2 activators '
    103 , 252-268 . [2015]
  • 'Peptide and small molecule inhibitors of the Keap1–Nrf2 protein– protein interaction
    43 ( 4 ) , 674-679 [2015]
  • 'Oxidative stress in metabolic disorders and drug-induced injury : the potential role of Nrf2 and PPARs activators '
    [2017]
  • 'Overcoming chemical , biological , and computational challenges in the development of inhibitors targeting protein-protein interactions
    22 ( 6 ) , 689-703 [2015]
  • 'Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson 's disease : critical role for the astrocyte
    106 ( 8 ) , 2933-2938 . [2009]
  • 'Nrf2 at the heart of oxidative stress and cardiac protection '
    50 ( 2 ) , 77-97 . [2018]
  • 'Nrf2 activation through the inhibition of Keap1–Nrf2 protein–protein interaction '
    29 , 846-867 . [2020]
  • 'Nrf2 activation in the treatment of neurodegenerative diseases : a focus on its role in mitochondrial bioenergetics and function
    397 ( 5 ) , 383-400 [2016]
  • 'Nrf2 , the master regulator of anti-oxidative responses
    18 ( 12 ) , 2772 . [2017]
  • 'Novel protein–protein interaction inhibitor of Nrf2– Keap1 discovered by structure-based virtual screening '
    5 ( 1 ) , 93-98 . [2014]
  • 'NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α
    71 ( 6 ) , 2260- 2275 . [2011]
  • 'NRF2 as a Therapeutic target in neurodegenerative diseases
    12 , 1759091419899782 [2020]
  • 'Multiple binding modes of a small molecule to human Keap1 revealed by X-ray crystallography and molecular dynamics simulation
    5 , 557-570 . [2015]
  • 'Monoacidic inhibitors of the Kelch-like ECHassociated protein 1 : nuclear factor erythroid 2-related factor 2 ( KEAP1 : NRF2 ) protein–protein interaction with high cell potency identified by fragment-based discovery
    59 ( 8 ) , 3991-4006 . [2016]
  • 'Molecular dynamics simulations and drug discovery
    9 ( 1 ) , 1-9 . [2011]
  • 'Molecular basis of electrophilic and oxidative defense : promises and perils of Nrf2
    64 ( 4 ) , 1055-1081 . [2012]
  • 'Kinetic , thermodynamic , and structural characterizations of the association between Nrf2-DLGex degron and Keap1
    34 ( 5 ) , 832-846 . [2014]
  • 'Keap1–Nrf2 pathway : A promising target towards lung cancer prevention and therapeutics
    1 ( 3 ) , 175-186 [2015]
  • 'Keap1 as the redox sensor of the antioxidant response
    [2017]
  • 'Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor ( Erythroid-Derived 2 ) -like 2 ( KEAP1-NRF2 ) Inhibitors with High Metabolic Stability '
    63 ( 12 ) , 6547-6560 . [2019]
  • 'Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-associated Protein 1 ( KEAP1 ) and Nuclear Factor , Erythroid 2 Like 2 ( Nrf2 )
    [2019]
  • 'Inhibitors of protein–protein interactions ( PPIs ) : an analysis of scaffold choices and buried surface area
    44 , 75-86 [2018]
  • 'Identification of novel indole derivatives acting as inhibitors of the Keap1–Nrf2 interaction '
    34 ( 1 ) , 1152-1157 [2019]
  • 'Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer ’ s disease
    26 ( 24 ) , 4823-4835 [2017]
  • 'Funnel metadynamics as accurate binding free-energy method
    110 ( 16 ) , 6358-6363 . [2013]
  • 'Fragment informatics and computational fragment‐ based drug design : an overview and update
    33 ( 3 ) , 554- 598 [2013]
  • 'Expression of Nrf2 in neurodegenerative diseases
    66 ( 1 ) , 75-85 [2007]
  • 'Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies
    23 ( 14 ) , 1875-1883 [2017]
  • 'Enhancing the Nrf2 antioxidant signaling provides protection against trichloroethene-mediated inflammation and autoimmune response
    175 ( 1 ) , 64-74 [2020]
  • 'Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress
    23 ( 22 ) , 8137-8151 . [2003]
  • 'Discovery of potent Keap1–Nrf2 protein–protein interaction inhibitor based on molecular binding determinants analysis '
    57 ( 6 ) , 2736-2745 . [2014]
  • 'Discovery of direct inhibitors of Keap1–Nrf2 protein–protein interaction as potential therapeutic and preventive agents
    5 ( 4 ) , 285-299 [2015]
  • 'Discovery of benzo [ g ] indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor '
    27 ( 22 ) , 5006-5009 . [2017]
  • 'Discovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interaction '
    23 ( 10 ) , 3039-3043 . [2013]
  • 'Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 ( Keap1–Nrf2 ) Protein–Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-Induced Hepatotoxicity '
    62 ( 14 ) , 6796-6813 . [2019]
  • 'Discovery of a Kelch-like ECH-associated protein 1-inhibitory tetrapeptide and its structural characterization '
    486 ( 3 ) , 620-625 . [2017]
  • 'Design , synthesis and identification of novel , orally bioavailable non-covalent Nrf2 activators
    30 ( 4 ) , 126852 . [2020]
  • 'Computer aided drug design : An overview
    8 ( 5 ) , 504-509 [2018]
  • 'Characterization of RA839 , a noncovalent small molecule binder to Keap1 and selective activator of Nrf2 signaling
    290 ( 47 ) , 28446-28455 [2015]
  • 'Binding mode and structure–activity relationships around direct inhibitors of the Nrf2–Keap1 complex
    9 ( 4 ) , 699-705 . [2014]
  • 'Basic concepts on the role of nuclear factor erythroid-derived 2-like 2 ( Nrf2 ) in age-related diseases
    20 ( 13 ) , 3208 . [2019]